Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
CAMP4 Therapeutics logo — Advancing a pipeline of ASO-based, RNA-targeting therapeutic...

CAMP4 Therapeutics

Advancing a pipeline of ASO-based, RNA-targeting therapeutics with the aim to restore healthy protein levels

Founded 2016 United States Cambridge, United States 61 employees Total: $290.00M Biopharma, Biotechnology +1

General Information

Company Name CAMP4 Therapeutics
Founded Year 2016
Location United States Cambridge, United States
Employees 61
Industries Biopharma, Biotechnology, Health and Wellness
Business Model B2B, B2C, B2D
Revenue Model Licensing, Performance Based, Project Based
Offices as of Nov 2026
‏Cambridge‏، ‏Massachusetts‏ ‏02139‏، ‏US‏, ‏Cambridge‏، ‏Massachusetts‏ ‏02139‏، ‏US‏
Social

BounceWatch is an independent company data service, not affiliated with CAMP4 Therapeutics. To contact CAMP4 Therapeutics, visit camp4tx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CAMP4 Therapeutics compare?

A PDF of CAMP4 Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CAMP4 Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Nov 03, 2026

CAMP4 Therapeutics is participating in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference.

Regulatory Approval Oct 27, 2026

CAMP4 Therapeutics received clearance from the European Medicines Agency to begin a Phase 1/2 clinical trial for CMP-002 in SYNGAP1 patients in the European Union.

CAMP4 Therapeutics a competitor of yours? Have our desk watch it

About CAMP4 Therapeutics

CAMP4 Therapeutics is a forward-thinking company in the biopharma and biotechnology sectors, founded in 2016 and headquartered in the United States. The company is on the cutting edge of developing ASO-based, RNA-targeting therapeutics with the aim of restoring healthy protein levels. Their approach focuses on programmable therapeutics to upregulate gene expression, potentially offering treatments for a wide range of diseases.

With their proprietary platform, CAMP4 Therapeutics leverages a deep understanding of regulatory RNA and gene expression. This innovative methodology could unlock treatments for hundreds of diseases, impacting millions of patients globally.

Significantly, the company secured a substantial $100.00M through a Private Placement Non VC investment on 01 September 2025, reflecting strong investor confidence. This influx of capital positions CAMP4 Therapeutics well to advance its therapeutic pipeline and drive future growth.

Business keywords: ASO-based therapeutics, RNA-targeting, Gene expression regulation, Oligonucleotide modality, Programmable therapeutics, RNA upregulation, Gene circuitry code, Proprietary insights, Gene production control, Cell signaling pathways, Disease treatment innovation, Therapeutic platform development, Molecular biology, Biomedical innovation, Protein level restoration

Services & Products

Development of RNA-based therapeutics
Modulation of gene expression
Preclinical research

Target Customers

Patient communities with limited treatment options Healthcare providers Pharmaceutical partners

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Private Placement Non VC $100.00M -
01 Sep 2025
IPO Undisclosed -
01 Oct 2024
Series B $100.00M 7
Gaingels Polaris Partners 5AM Ventures
Gaingels, Polaris Partners +5
01 Jul 2022
Early VC $45.00M 5
Polaris Partners 5AM Ventures Andreessen Horowitz/ a16z
Polaris Partners, 5AM Ventures +3
01 Jun 2021
Early VC $15.00M -
01 Jan 2020
Series A $30.00M 3
Polaris Partners Andreessen Horowitz/ a16z The Kraft Group
Polaris Partners, Andreessen Horowitz/ a16z +1
01 Jun 2018
Spinout Undisclosed 3
Boston Capital
Boston Capital, Massachusetts Institute of Technology +1
01 Jan 2016

CAMP4 Therapeutics Alternatives & Competitors

View All Alternatives
CAMP4 Therapeutics vs
miRecule, Inc.
miRecule, Inc. United States

RNA Therapeutics

Seed
12 employees
Biopharma, Biotechnology
Compare CAMP4 Therapeutics vs miRecule, Inc.
CAMP4 Therapeutics vs
Orna Therapeutics
Orna Therapeutics United States

Wholly Owned Subsidiary of Eli Lilly and Company

Corporate
127 employees
Biotechnology, Health and Wellness
Compare CAMP4 Therapeutics vs Orna Therapeutics
CAMP4 Therapeutics vs
Arbor Biotechnologies
Arbor Biotechnologies United States

Genetic medicines for genetic diseases

101 employees
Biopharma, Biotechnology
View all alternatives

FAQ About CAMP4 Therapeutics

Advancing a pipeline of ASO-based, RNA-targeting therapeutics with the aim to restore healthy protein levels
CAMP4 Therapeutics was founded in 2016.
CAMP4 Therapeutics is headquartered in Cambridge, United States. As of Nov 2026, it also has offices in ‏Cambridge‏، ‏Massachusetts‏ ‏02139‏، ‏US‏, ‏Cambridge‏، ‏Massachusetts‏ ‏02139‏، ‏US‏.
CAMP4 Therapeutics operates in Biopharma, Biotechnology and Health and Wellness. Its work centres on ASO-based therapeutics, RNA-targeting, Gene expression regulation and Oligonucleotide modality. Its customers include Patient communities with limited treatment options, Healthcare providers and Pharmaceutical partners.
CAMP4 Therapeutics has a B2B, B2C and B2D business model. Its revenue comes from Licensing, Performance Based and Project Based.
CAMP4 Therapeutics has approximately 61 employees.
CAMP4 Therapeutics has completed 7 funding rounds, raising a total of $290.00M.
CAMP4 Therapeutics offers: Development of RNA-based therapeutics, Modulation of gene expression, Preclinical research.
Top alternatives and competitors to CAMP4 Therapeutics include miRecule, Inc., Orna Therapeutics, Arbor Biotechnologies, Rgenta Therapeutics Inc., Cajal Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CAMP4 Therapeutics and miRecule, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CAMP4 Therapeutics, https://bouncewatch.com/company/camp4-therapeutics, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout